Navigation Links
BNC105 Biomarker Data to Be Presented at Asian Oncology Conference
Date:4/10/2015

ADELAIDE, Australia, April 10, 2015 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQX: BNOEF) today announced that it will present a poster with new data on the DisrupTOR-1 trial of BNC105 in patients with metastatic renal cancer at the 7th Asian Oncology Summit being held from April 10-12, 2015 in Shanghai, China.

The poster will be presented by Dr. Jeremy Simpson, Vice President, Clinical Development at Bionomics, and is entitled, A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC): Results of the randomized phase II DisrupTOR-1 trial. The Poster Walk session is during the Welcome Reception on Friday, April 10th, 2015 at 5:45 p.m. CST in the Mandarin Hall of the Oriental Riverside Hotel and Convention Centre .

The data identify ferritin and IL-8 as two baseline biomarkers that correlate with an improved progression free survival (PFS) in patients. Eighty nine percent of patients expressing higher plasma levels of ferritin and lower plasma levels of IL-8 at baseline were disease progression-free at six months. The data show that biomarker-based patient selection has the potential to optimise clinical outcomes in the treatment of renal cancer. There are 6.3 new cases of renal cancer and 1.7 deaths per 100,000 people in Asia each year. 

BNC105 is a novel compound being developed as a vascular disrupting agent (VDA) for the treatment of cancer. VDAs are drugs that disrupt the blood vessels that nourish tumours. This approach has a number of advantages over classical chemotherapy, including stronger impact on tumour cell death, applicability to a wider variety of cancers, and lowered risk of the emergence of therapy-resistant tumour cells.

FOR FURTHER INFORMATION PLEASE CONTACT:Bionomics LimitedMonsoon CommunicationsStern IR Dr Deborah Rathjen

Rudi Michelson

Beth DelGiaccoCEO & Managing Director

+61 (0)3 9620 3333

+1 (212) 362 1200+61 (0)8 8354 6101

rudim@monsoon.com.au

beth@sternir.com 0418 160 425drathjen@bionomics.com.auAbout Bionomics LimitedBionomics (ASX: BNO) is a biopharmaceutical company that discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, memory loss and pain. Its oncology approach includes cancer stem cell therapeutics as well as vascular disruption in solid tumours.

Bionomics' discovery and development are driven by its four proprietary technology platforms: MultiCore®, a diversity orientated chemistry platform for the discovery of small molecule drugs; ionX® , a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system; Angene®, a drug discovery platform that incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels); and CSC Rx Discovery™, which identifies antibody and small molecule therapeutics that inhibit the growth of cancer stem cells. These platforms drive Bionomics' pipeline and underpin its established business strategy of securing partners for its key compounds. Bionomics' partners include Merck & Co.
www.bionomics.com.au

Factors Affecting Future PerformanceThis announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' development candidates BNC105, BNC210, BNC101 and BNC375, our acquisition of Eclipse Therapeutics and ability to develop products from their platform, its licensing deals with Merck & Co, drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, Merck's decisions to continue or not to continue development of partnered compounds, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors' products may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

 

 


'/>"/>
SOURCE Bionomics Limited
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Start von Project Survival(SM): Kooperation zielt darauf ab, den allerersten Biomarker für Bauchspeicheldrüsenkrebs zu entdecken
2. Advanced Cell Diagnostics RNAscope Technology Supports Biomarker-Selected Phase 2 Clinical Trial of Merrimack Pharmaceuticals MM-121
3. Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests
4. Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery
5. Caris Life Sciences Multiplatform Tumor Profiling Helps to Identify Potential Predictive Biomarkers in Renal Cell Carcinoma
6. ViveBio, LLC Enters Worldwide Exclusive Licensing Agreement with Renovar Inc. for Novel Urine Based Biomarker Technologies Covering Kidney Disease and Transplant Monitoring
7. Nektar Presents Data on Target-Specific Biomarkers from Circulating Tumor Cell Sub-Study of Phase 3 BEACON Study of Etirinotecan Pegol (NKTR-102) in Patients with Advanced Breast Cancer
8. Global Cardiac Biomarkers Market 2014-2018: Key Vendors are Abbott Laboratories, Alere, Ortho Clinical Diagnostics and Roche Diagnostics
9. Medical Diagnostic Laboratories, L.L.C. Institute for Biomarker Research Announces New Prenatal Cystic Fibrosis Tests
10. Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip
11. Cypher Genomics Forms Scientific Advisory Board to Advance Genome Interpretation and Biomarker Discovery Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2020)... LOS GATOS, Calif. (PRWEB) , ... January 08, ... ... Poelstra, of The Robotic Spine Institute of Silicon Valley, has this week announced ... the West Coast using a Molybdenum-Rhenium rod in a patient. , The newly ...
(Date:1/8/2020)... PHOENIX (PRWEB) , ... January 09, 2020 , ... R3 ... for providers, including over 50 first rate presentations and procedure videos. The course is ... for one's malpractice carrier. , For years, R3 Stem Cell has been the leader ...
(Date:1/7/2020)... ... January 07, 2020 , ... ... (BP) sensor system for integration in hearables and wearables. Valencell will provide the ... manufacturers for inclusion in their products. Embedded in an earbud reference design, the ...
Breaking Medicine Technology:
(Date:1/7/2020)... ... ... Destressing the patient payment and billing experience, balancing accelerating cash and reducing bad debt, ... examined at the HFMA Western Symposium, to be held January 12-15, 2019, at the ... in supporting hospitals to more effectively source and manage revenue cycle vendors, will moderate ...
(Date:1/7/2020)... ... January 07, 2020 , ... Iconic singer, choreographer and actress ... one of the most successful female artists of all time, but also for looking ... Vegas residency and shared in interviews her secrets to making it through 10 hour ...
(Date:1/7/2020)... , ... January 07, 2020 , ... ... Training Course , which includes comprehensive presentations and procedures for hair restoration, facial ... a completion certificate available. , Regenerative aesthetics has become incredibly popular over the ...
(Date:1/5/2020)... ... , ... Urban Air, the premier family-friendly indoor trampoline and entertainment center, wants ... hours of trampolining, rock climbing, dodge-balling and more, has announced the location of its ... “We know families are looking for ways to spend time together – and the ...
(Date:1/2/2020)... Calif. (PRWEB) , ... January 02, 2020 , ... NEA ... new Jeep® Compass* from California Casualty . , Educators lead extremely busy ... they are behind the wheel. From smartphones to navigation devices, new technology is a ...
Breaking Medicine News(10 mins):